Skip to main content

Table 3 Market shares of conventional recombinant products for paediatric and adult patients

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

  Paediatrics Adults
Advate® 30% 24%
Kogenate® 29% 23%
Refacto® 23% 18%
Helixate® 17% 13%
Recombinate® 1% 1%
Plasma-derived products 21%